AnPac Bio-Medical Science Co. Ltd. (ANPC)

NASDAQ: ANPC · IEX Real-Time Price · USD
0.141
-0.007 (-4.47%)
Sep 27, 2022 2:51 PM EDT - Market closed
-4.47%
Market Cap 5.54M
Revenue (ttm) 2.78M
Net Income (ttm) -16.30M
Shares Out 39.26M
EPS (ttm) -1.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 312,272
Open 0.148
Previous Close 0.148
Day's Range 0.141 - 0.164
52-Week Range 0.130 - 3.534
Beta 1.30
Analysts Buy
Price Target 8.16 (+5,679.0%)
Earnings Date Sep 29, 2022

About ANPC

AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China. [Read more...]

Industry Biotechnology
IPO Date Jan 30, 2020
Employees 89
Stock Exchange NASDAQ
Ticker Symbol ANPC
Full Company Profile

Financial Performance

In 2021, ANPC's revenue was 17.99 million, a decrease of -12.30% compared to the previous year's 20.51 million. Losses were -118.70 million, 47.5% more than in 2020.

Financial numbers in CNY Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ANPC stock is "Buy." The 12-month stock price forecast is 8.16, which is an increase of 5,679.04% from the latest price.

Price Target
$8.16
(5,679.04% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China f...

17 hours ago - GlobeNewsWire

AnPac Bio Appeals NASDAQ Delisting Notice; Hearing Granted and Scheduled for October 20, 2022

PHILADELPHIA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China f...

1 week ago - GlobeNewsWire

AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Appeal

PHILADELPHIA, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China f...

2 weeks ago - GlobeNewsWire

AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer

PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China fo...

1 month ago - GlobeNewsWire

AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers,...

PHILADELPHIA, July 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China fo...

2 months ago - GlobeNewsWire

AnPac Bio Regains Compliance with Requirements to Remain Listed on Nasdaq Capital Market

PHILADELPHIA, June 10, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China fo...

3 months ago - GlobeNewsWire

AnPac Bio Reports 49.1% Decrease in Net Loss in First Quarter of Fiscal 2022

PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United St...

3 months ago - GlobeNewsWire

AnPac Bio Reports Fiscal Year 2021 Annual Financial Results

PHILADELPHIA, May 16, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United St...

4 months ago - GlobeNewsWire

AnPac Bio Regains Compliance with Market-Value-Of-Publicly Held Shares Requirement upon Transfer to The Nasdaq Capita...

PHILADELPHIA, May 11, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China foc...

4 months ago - GlobeNewsWire

Nasdaq Hearing Panel Grants AnPac Bio's Request to Transfer Securities from The Nasdaq Global Market to The Nasdaq Ca...

PHILADELPHIA, May 06, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China foc...

4 months ago - GlobeNewsWire

AnPac Bio and New Investor Sign Equity Investment Totaling $15 Million

PHILADELPHIA, April 11, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China f...

5 months ago - GlobeNewsWire

AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a N...

PHILADELPHIA, April 08, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China f...

5 months ago - GlobeNewsWire

AnPac Bio Filed Request for a Hearing Regarding Continued Listing on NASDAQ, The Hearing was Granted and scheduled fo...

PHILADELPHIA, April 04, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China f...

5 months ago - GlobeNewsWire

AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

PHILADELPHIA, March 26, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China f...

6 months ago - GlobeNewsWire

AnPac Bio-Medical Sciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

PHILADELPHIA, March 11, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China f...

6 months ago - GlobeNewsWire

AnPac Bio's Bio-Chip Subsidiary, Changwei System Technology Co., Ltd., Receives Independent Valuation and Approval fr...

PHILADELPHIA, March 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China f...

6 months ago - GlobeNewsWire

AnPac Bio Files CDA Device for Breakthrough Medical Device Designation Request with the FDA

PHILADELPHIA, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China fo...

7 months ago - GlobeNewsWire

Leading US Market Analysis and Research Firm Ranked AnPac Bio Globally Number One in Multi-Cancer Screening and Detec...

PHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China fo...

8 months ago - GlobeNewsWire

AnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

PHILADELPHIA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and ...

8 months ago - GlobeNewsWire

AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in Q1, 2022

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a US and China-based biotechnology company focused on early cancer screen...

8 months ago - GlobeNewsWire

Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical J...

PHILADELPHIA, Dec. 10, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United S...

9 months ago - GlobeNewsWire

AnPac Bio Reports Nine Months Ended September 30, 2021, Same Period Achieved Record Revenue Increased By 55.3% While ...

PHILADELPHIA, Nov. 26, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United S...

10 months ago - GlobeNewsWire

CORRECTION -- Anpac Bio, USA

PHILADELPHIA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- In its press release dated November 9, 2021 entitled “AnPac Bio Announces Pricing of Approximately $2.9 Million Underwritten Public Offering of American D...

10 months ago - GlobeNewsWire

AnPac Bio Announces Pricing of Approximately $2.9 Million Underwritten Public Offering of American Depositary Shares

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with operations in China and the United States focusing on earl...

10 months ago - GlobeNewsWire

UPDATE - AnPac Bio Commences Proposed Public Offering of American Depositary Shares

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC, the “Company”), a biotechnology company with operations in China and the United States focusing on earl...

10 months ago - GlobeNewsWire